Cassava Sciences Inc. (SAVA) Financial Statements (2024 and earlier)
Company Profile
Business Address |
6801 N CAPITAL OF TEXAS HIGHWAY AUSTIN, TX 78731 |
State of Incorp. | DE |
Fiscal Year End | December 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 124,169,000 | 121,136,000 | 142,350,000 | 168,438,000 | 187,467,000 | 201,015,000 | |||
Cash and cash equivalents | 124,169,000 | 121,136,000 | 142,350,000 | 168,438,000 | 187,467,000 | 201,015,000 | |||
Receivables | 1,000,000 | 962,000 | 1,285,000 | 1,328,000 | |||||
Prepaid expense | 382,000 | 759,000 | 1,136,000 | 240,000 | 716,000 | 1,034,000 | |||
Other current assets | 218,000 | 287,000 | 189,000 | ||||||
Other undisclosed current assets | 8,230,000 | 6,489,000 | 5,224,000 | 4,527,000 | 6,816,000 | 9,177,000 | |||
Total current assets: | 133,999,000 | 129,633,000 | 150,184,000 | 174,533,000 | 194,999,000 | 211,226,000 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 122,000 | ||||||||
Property, plant and equipment | 21,604,000 | 21,854,000 | 22,077,000 | 22,328,000 | 22,609,000 | 22,864,000 | |||
Intangible assets, net (including goodwill) | 115,000 | 176,000 | 268,000 | 387,000 | 503,000 | 622,000 | |||
Intangible assets, net (excluding goodwill) | 115,000 | 176,000 | 268,000 | 387,000 | 503,000 | 622,000 | |||
Total noncurrent assets: | 21,719,000 | 22,030,000 | 22,345,000 | 22,715,000 | 23,112,000 | 23,608,000 | |||
TOTAL ASSETS: | 155,718,000 | 151,663,000 | 172,529,000 | 197,248,000 | 218,111,000 | 234,834,000 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 228,000 | 200,000 | 187,000 | 17,382,000 | 13,518,000 | 6,297,000 | |||
Accounts payable | 10,338,000 | 8,242,000 | 4,017,000 | ||||||
Accrued liabilities | 228,000 | 200,000 | 187,000 | 7,044,000 | 5,276,000 | 2,280,000 | |||
Derivative instruments and hedges, liabilities | 65,368,000 | ||||||||
Other liabilities | 125,000 | 385,000 | 391,000 | 293,000 | 179,000 | 492,000 | |||
Other undisclosed current liabilities | 11,400,000 | 13,610,000 | 16,836,000 | 220,000 | 212,000 | 274,000 | |||
Total current liabilities: | 77,121,000 | 14,195,000 | 17,414,000 | 17,895,000 | 13,909,000 | 7,063,000 | |||
Noncurrent Liabilities | |||||||||
Liabilities, other than long-term debt | 197,000 | 232,000 | |||||||
Other liabilities | 197,000 | 197,000 | |||||||
Operating lease, liability | 35,000 | ||||||||
Total noncurrent liabilities: | 197,000 | 232,000 | |||||||
Total liabilities: | 77,121,000 | 14,195,000 | 17,414,000 | 17,895,000 | 14,106,000 | 7,295,000 | |||
Equity | |||||||||
Equity, attributable to parent | 78,597,000 | 137,468,000 | 155,115,000 | 179,353,000 | 204,005,000 | 227,539,000 | |||
Common stock | 43,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | |||
Additional paid in capital | 434,280,000 | 518,195,000 | 514,923,000 | 513,510,000 | 511,786,000 | 511,049,000 | |||
Accumulated deficit | (355,726,000) | (380,769,000) | (359,850,000) | (334,199,000) | (307,823,000) | (283,552,000) | |||
Total equity: | 78,597,000 | 137,468,000 | 155,115,000 | 179,353,000 | 204,005,000 | 227,539,000 | |||
TOTAL LIABILITIES AND EQUITY: | 155,718,000 | 151,663,000 | 172,529,000 | 197,248,000 | 218,111,000 | 234,834,000 |
Income Statement (P&L) (USD)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
---|---|---|---|---|---|---|---|---|
Operating expenses | (19,934,000) | (22,789,000) | (27,879,000) | (28,777,000) | (26,512,000) | (20,937,000) | ||
Operating loss: | (19,934,000) | (22,789,000) | (27,879,000) | (28,777,000) | (26,512,000) | (20,937,000) | ||
Nonoperating income (Other Nonoperating income) | 160,000 | 291,000 | 223,000 | 203,000 | 190,000 | 249,000 | ||
Net loss: | (19,774,000) | (22,498,000) | (27,656,000) | (28,574,000) | (26,322,000) | (20,688,000) | ||
Other undisclosed net income attributable to parent | 44,817,000 | 1,579,000 | 2,005,000 | 2,198,000 | 2,051,000 | 1,554,000 | ||
Net income (loss) attributable to parent: | 25,043,000 | (20,919,000) | (25,651,000) | (26,376,000) | (24,271,000) | (19,134,000) | ||
Preferred stock dividends and other adjustments | (43,792,000) | |||||||
Net income (loss) available to common stockholders, basic: | (18,749,000) | (20,919,000) | (25,651,000) | (26,376,000) | (24,271,000) | (19,134,000) | ||
Dilutive securities, effect on basic earnings per share | (43,792,000) | |||||||
Other undisclosed net income available to common stockholders, diluted | 43,792,000 | |||||||
Net income (loss) available to common stockholders, diluted: | (18,749,000) | (20,919,000) | (25,651,000) | (26,376,000) | (24,271,000) | (19,134,000) |
Comprehensive Income (USD)Annual | Quarterly
6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (19,774,000) | (22,498,000) | (27,656,000) | (28,574,000) | (26,322,000) | (20,688,000) | ||
Comprehensive loss, net of tax, attributable to parent: | (19,774,000) | (22,498,000) | (27,656,000) | (28,574,000) | (26,322,000) | (20,688,000) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.